FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam

CHICAGO (Reuters) – Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company’s shares down 4.6 percent in after-hours trading.

The study compared the drug, called selonsertib, with a placebo treatment in a trial of nearly 900 patients with compensated cirrhosis, an advanced form of Nonalcoholic Steatohepatitis, or NASH.

“While we are disappointed that the STELLAR-4 study did not achieve its primary endpoint, we remain committed to advancing therapies for patients with advanced fibrosis due to NASH, where there is a significant unmet need for effective and well-tolerated treatments,” Dr. John McHutchison, Gilead’s chief scientific officer, said in a statement.

Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as populations with fatty diets increasingly develop the disease.

Reporting by Julie Steenhuysen; Editing by Dan Grebler



READ SOURCE

READ  What is monkeypox, is it deadly, how do you catch it and what are the common signs, symptoms and treatments of the disease?

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here